German company CureVac reported the results of the second interim analysis of the vaccine against coronavirus. Its effectiveness is 47 percent.
“Today, CureVac announced the results of a second interim analysis of its (…) Phase 2b/3 study of its first-generation CVnCoV candidate vaccine against COVID-19 in approximately 40,000 volunteers. (…) The vaccine showed an interim efficacy of 47 percent against any severity of COVID-19. which did not meet the previously set criteria for statistical success,” the statement said. CureVac added that the information has been submitted to the European Medicines Agency (EMA), and the study continues until final analysis.
Germany’s CureVac has a contract with the European Commission to supply the vaccine centrally to EU countries going forward. In February, CureVac began a progressive review process for the vaccine, which was planned to be released in 2022 with up to a billion doses. CVnCoV began developing the vaccine in January 2020 and has been conducting clinical trials since July. The final stages began in late 2020. If successful, the vaccine will be produced in Tübingen, Germany.
Earlier, Rospotrebnadzor reported that Russian vaccines against coronavirus passed the necessary tests to assess the impact on the ability to have children. Experts assured that no negative effects of vaccination were revealed during the relevant tests, and the vaccination is not a contraindication for pregnancy.